IMA901 is a therapeutic cancer vaccine comprising 10 tumor-associated peptides (TUMAPs) that are frequently found to be over-expressed in the majority of patients suffering from renal cell carcinoma.
The primary endpoint of the trial will be the overall survival of patients with advanced renal cell carcinoma treated with IMA901 in conjunction with Pfizer’s Sutent (sunitinib malate) versus Sutent alone.
Pfizer is expected to supply Sutent for all the patients recruited in the pivotal study.
Immatics CEO Paul Higham said they are pleased that Pfizer has committed to support their pivotal Phase III trial of IMA901 with the supply of Sutent.
Pfizer Oncology Strategic Alliances and Partnerships vice president Craig Eagle said Pfizer is pleased to provide Sutent to support immatic’s clinical development program in advanced renal cell carcinoma patients.